ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.802,06
-0,19%
S&P 500
5.291,34
0,15%
US Dollar vs BRL
5,2901
0,02%
Bitcoin
71.013,46
0,55%
Brent Oil
77,545
0,56%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Alkermes PLC (ALKS)

  7. Alkermes PLC (ALKS) Notícias

ALKS Alkermes PLC

23,65
0,00 (0,00%)
Pré-mercado
Última atualização: 05:05:36
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Alkermes PLC ALKS NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,00 0,00% 23,65 05:05:36
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
23,65
mais cotações »

Notícias Recentes

Data Hora Fonte Título
03/06/202408:00PRNUSAlkermes Presents Data From Phase 1b Study of ALKS 2680..
29/05/202417:00PRNUSAlkermes to Participate in Two Upcoming Investor Conferences
28/05/202408:00PRNUSAlkermes to Present New Clinical Data for ALKS 2680 at SLEEP..
14/05/202408:00PRNUSAlkermes Highlights Data Presentations Related to its..
02/05/202408:00PRNUSAlkermes plc Completes Sale of Athlone, Ireland Facility to..
01/05/202408:00PRNUSAlkermes plc Reports First Quarter 2024 Financial Results
24/04/202408:00PRNUSAlkermes Announces Initiation of Vibrance-1 Phase 2 Study..
17/04/202417:00PRNUSAlkermes to Report First Quarter Financial Results on May 1,..
09/04/202408:00PRNUSAlkermes Announces Positive Topline Results From Phase 1b..
08/04/202408:00PRNUSAlkermes Presents Analyses From Long-Term Safety Study of..
07/03/202409:00PRNUSAlkermes Announces Appointment of Nancy S. Lurker to Board..
15/02/202409:00PRNUSAlkermes plc Reports Financial Results for the Fourth..
08/02/202418:00PRNUSAlkermes to Report Fourth Quarter and Year-End Financial..
03/01/202418:00PRNUSAlkermes to Present at the 42nd Annual J.P. Morgan..
03/01/202409:00PRNUSAlkermes Announces Topline Results From Long-Term,..
14/12/202308:05PRNUSAlkermes plc Announces Agreement to Sell Athlone, Ireland..
01/12/202320:16PRNUSUber Technologies, Jabil and Builders FirstSource Set to..
21/11/202318:00PRNUSAlkermes to Participate in Two Upcoming Investor Conferences
15/11/202309:00PRNUSAlkermes Completes Separation of Oncology Business
07/11/202318:00PRNUSAlkermes to Participate in the Jefferies London Healthcare..
31/10/202318:18PRNUSAlkermes Announces Effectiveness of Mural Oncology Form 10..
31/10/202318:08PRNUSAlkermes Announces Effectiveness of Mural Oncology Form 10..
25/10/202308:00PRNUSAlkermes plc Reports Third Quarter 2023 Financial Results
23/10/202309:00PRNUSAlkermes Presents First Clinical Data for Orexin 2 Receptor..
18/10/202317:00PRNUSAlkermes to Report Third Quarter Financial Results on..
10/10/202318:00PRNUSMural Oncology to Host Investor Webcast on October 17
10/10/202308:00PRNUSAlkermes to Present First Clinical Data for Orexin 2..
11/09/202308:00PRNUSAlkermes Presents Clinical and Real-World Data at 36th..
07/09/202308:00PRNUSAlkermes Announces Launch of 6th Annual Alkermes Pathways..
05/09/202317:00PRNUSAlkermes to Participate in Two Upcoming Investor Conferences
31/08/202308:00PRNUSAlkermes Announces Recipients of 2023 Alkermes Inspiration..
30/08/202308:00PRNUSAlkermes Announces Settlement With Teva Related to VIVITROL®..
26/07/202308:00PRNUSAlkermes plc Reports Second Quarter 2023 Financial Results
19/07/202317:31PRNUSAlkermes to Report Second Quarter Financial Results on July..
19/07/202317:03PRNUSAlkermes to Report Second Quarter Financial Results on July..
29/06/202311:54PRNUSAlkermes Shareholders Re-Elect All Seven Company Director..
29/06/202311:50PRNUSAlkermes Shareholders Re-Elect All Seven Company Director..
28/06/202308:30BWSarissa Capital Urges Alkermes Shareholders to Vote “FOR”..
26/06/202308:37BWSarissa Issues Presentation Highlighting Sarissa Nominees..
26/06/202308:00PRNUSRecently-Appointed Independent Directors of Alkermes Issue..
22/06/202307:25BWIndependent Proxy Advisory Firm ISS Agrees With Sarissa..
21/06/202309:00PRNUSIndependent Proxy Advisory Firm Glass Lewis Recommends..
20/06/202310:33BWIndependent Proxy Advisory Firm ISS Concludes That Sarissa..
20/06/202308:00PRNUSIndependent Proxy Advisory Firm ISS Recommends Alkermes..
15/06/202308:58BWSarissa Issues Presentation Highlighting the Need for..
13/06/202308:20BWSarissa Urges Shareholders to Vote for Sarissa Nominees to..
13/06/202308:00PRNUSAlkermes Issues Letter to Shareholders Highlighting Skills..
09/06/202308:00BWSarissa Capital Highlights Misleading Claims Made by..
08/06/202308:00PRNUSAlkermes Publishes Investor Presentation Detailing Company's..
06/06/202307:00PRNUSAlkermes Announces Final Award in Janssen Pharmaceutica..

Seu Histórico Recente

NASDAQ
ALKS
Alkermes
COIN
ADAEUR
Cardano
BIT
P20VQ3
NLBNPIT20VQ3 20240920 110
UNSW3
ANMLETH
Animal Concerts Token
BIT
S32151
Societe Generale Effekten
USOTC
STQN
Strategic Aquisitions (PK)
COIN
CELCBTC
CelCoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados